Literature DB >> 8788155

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

M T Huizing1, A Sparreboom, H Rosing, O van Tellingen, H M Pinedo, J H Beijnen.   

Abstract

A reversed-phase high-performance liquid chromatographic (HPLC) method has been validated for the quantitative determination of the three major paclitaxel metabolites (6 alpha-hydroxypaclitaxel, 3'-p-hydroxypaclitaxel, 6 alpha,3'-p-dihydroxypaclitaxel) in human plasma. The HPLC system consists of an APEX-octyl analytical column and acetonitrile-methanol-0.02 M ammonium acetate buffer pH 5 (AMW; 4:1:5, v/v/v) as the mobile phase. Detection is performed by UV absorbance measurement at 227 nm. The sample pretreatment of the plasma samples involves solid-phase extraction (SPE) on Cyano Bond Elut columns. The concentrations of the metabolic products could be determined by using the paclitaxel standard curve with a correction factor of 1.14 for 6 alpha,3'-p-dihydroxypaclitaxel. The recoveries of paclitaxel and the metabolites 6 alpha,3'-p-dihydroxypaclitaxel, 3'-p-hydroxypaclitaxel and 6 alpha-hydroxypaclitaxel in human plasma were 89, 78, 91 and 89%, respectively. The accuracy of the assay for the determination of paclitaxel and its metabolites varied between 95 and 97%, at a 50 ng/ml analyte concentration. The lower limit of quantitation was 10 ng/ml for both the parent drug and its metabolites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8788155     DOI: 10.1016/0378-4347(95)00308-8

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  10 in total

1.  Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

Authors:  Markus Joerger; Stefanie Kraff; Alwin D R Huitema; Gary Feiss; Berta Moritz; Jan H M Schellens; Jos H Beijnen; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

Authors:  Roos L Oostendorp; T Buckle; G Lambert; J S Garrigue; J H Beijnen; J H M Schellens; O van Tellingen
Journal:  Invest New Drugs       Date:  2010-04-13       Impact factor: 3.850

3.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

4.  Human liver microsomal metabolism of paclitaxel and drug interactions.

Authors:  P B Desai; J Z Duan; Y W Zhu; S Kouzi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

5.  Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.

Authors:  Kai Jie Chen; Wan Yi Chen; Xia Chen; Yi Ming Jia; Gui Qin Peng; Li Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-05-17       Impact factor: 2.441

6.  Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

Authors:  M Joerger; A D R Huitema; M T Huizing; P H B Willemse; A de Graeff; H Rosing; J H M Schellens; J H Beijnen; J B Vermorken
Journal:  Br J Clin Pharmacol       Date:  2007-11       Impact factor: 4.335

7.  The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Authors:  M M Malingré; J H Schellens; O Van Tellingen; M Ouwehand; H A Bardelmeijer; H Rosing; F J Koopman; M E Schot; W W Ten Bokkel Huinink; J H Beijnen
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

8.  Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

Authors:  O van Tellingen; M T Huizing; V R Panday; J H Schellens; W J Nooijen; J H Beijnen
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

9.  Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.

Authors:  M M Malingré; J H Beijnen; H Rosing; F J Koopman; R C Jewell; E M Paul; W W Ten Bokkel Huinink; J H Schellens
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

10.  Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.

Authors:  C Martínez; E García-Martín; R M Pizarro; F J García-Gamito; J A G Agúndez
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.